#glioblastoma treatment

[global-cancer-technology]

Glioblastoma Cancer Treatment Technology Center

If you’re one of the 10,000 people in the USA diagnosed or a family member of one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. Nearly all patients diagnosed die within 12-18 months.

At the glioblastoma treatment technology center, Global Cancer Technology is investigating novel approaches to combat serious diseases like Glioblastoma Cancer.

[mmarketdbmr]

 Glioblastoma Multiforme Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032 Companies: Growth, Share, Value, Analysis, and Trends

"Glioblastoma Multiforme Treatment Market Size And Forecast by 2032

According to Data Bridge Market Research Global glioblastoma multiforme treatment market size was valued at USD 3.09 billion in 2024 and is projected to reach USD 6.44 billion by 2032, with a CAGR of 8.90% during the forecast period of 2025 to 2032.

Our comprehensive Glioblastoma Multiforme Treatment Market report is ready with the latest trends, growth opportunities, and strategic analysis. https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market

**Segments**

- **Treatment Type**: The Glioblastoma Multiforme Treatment Market can be segmented based on treatment type, including surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and supportive care. Surgery plays a crucial role in removing as much of the tumor as possible, while chemotherapy and radiation therapy are often used as adjuvant treatments to target remaining cancer cells. Targeted therapy aims to attack specific molecules involved in cancer growth, whereas immunotherapy boosts the body's immune response against cancer cells. Supportive care focuses on managing symptoms and improving the quality of life for patients.

- **End-User**: Another key segmentation factor is the end-user of Glioblastoma Multiforme treatments. This includes hospitals, clinics, ambulatory surgical centers, and research institutes. Hospitals are the primary point of care for most Glioblastoma patients, where they receive a range of treatments and support services. Clinics and ambulatory surgical centers may also provide specialized care for Glioblastoma patients, while research institutes drive innovation in treatment options through clinical trials and experimental therapies.

- **Region**: Geographically, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America, particularly the United States, holds a significant share in the Glioblastoma Multiforme Treatment Market due to advanced healthcare infrastructure, higher healthcare spending, and a strong focus on research and development. Europe follows closely behind, with countries like Germany, the UK, and France contributing to market growth. The Asia Pacific region is also emerging as a lucrative market for Glioblastoma treatments, fueled by improving healthcare access and rising awareness.

**Market Players**

- **Merck & Co., Inc.**: One of the leading players in the Glioblastoma Multiforme Treatment Market, Merck & Co. offers a range of oncology therapies, including treatments for Glioblastoma. The company's innovative approach to drug development and strong research capabilities make it a key player in the market.

- **Bristol-Myers Squibb Company**: Another prominent market player, Bristol-Myers Squibb, focuses on developing immunotherapy and targeted therapy options for Glioblastoma patients. The company's commitment to innovation and patient-centric solutions sets it apart in the competitive landscape.

- **Eli Lilly and Company**: Known for its portfolio of cancer treatments, Eli Lilly is actively involved in Glioblastoma Multiforme research and development. The company's global presence and dedication to improving treatment outcomes make it a significant player in the market.

- **Tocagen Inc.**: Specializing in gene therapy for Glioblastoma and other cancers, Tocagen is a key player driving advancements in treatment options. The company's focus on personalized medicine and cutting-edge technologies cements its position in the market.

The Glioblastoma Multiforme Treatment Market is a dynamic and competitive space, with key players continually innovating to meet the complex needs of patients. As research and development efforts progress, the market is expected to witness significant growth and advancements in treatment options.

https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market The Glioblastoma Multiforme Treatment Market is witnessing significant growth propelled by increasing incidence rates of brain tumors, advancements in healthcare infrastructure, and ongoing research and development efforts by key market players. The market is segmented based on treatment type, end-user, and region, offering a comprehensive view of the diverse factors influencing market dynamics. Surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and supportive care are key treatment modalities driving the market forward. Each treatment type plays a crucial role in managing Glioblastoma and improving patient outcomes.

End-users in the market, including hospitals, clinics, ambulatory surgical centers, and research institutes, play a vital role in delivering care to Glioblastoma patients. Hospitals serve as the primary care setting for most patients, offering a wide range of treatment options and support services. Clinics and ambulatory surgical centers provide specialized care, while research institutes drive innovation through clinical trials and experimental therapies. The collaboration between different end-users contributes to the overall growth and development of the Glioblastoma Multiforme Treatment Market.

Geographically, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are prominent regions in the Glioblastoma Multiforme Treatment Market. North America leads the market due to its advanced healthcare infrastructure, robust research and development activities, and higher healthcare spending. Europe closely follows, with countries like Germany, the UK, and France contributing significantly to market growth. The Asia Pacific region is rapidly emerging as a lucrative market for Glioblastoma treatments, driven by improving healthcare access and rising awareness about brain tumors.

Key market players such as Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and Tocagen Inc. are at the forefront of driving innovation and advancements in Glioblastoma treatment options. These companies offer a range of therapies, including immunotherapy, targeted therapy, and gene therapy, to cater to the complex needs of Glioblastoma patients. Their commitment to research and development, patient-centric solutions, and global presence position them as significant players in the competitive landscape.

Overall, the Glioblastoma Multiforme Treatment Market is a dynamic and competitive space characterized by ongoing advancements and collaboration among key market players. As research efforts progress and innovative therapies continue to emerge, the market is poised for substantial growth and improved treatment outcomes for Glioblastoma patients worldwide.**Segments**

- **Global Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administration (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Industry Trends and Forecast to 2032**

The global Glioblastoma Multiforme Treatment Market is segmented based on various factors influencing the industry landscape. Market segmentation is crucial in understanding the diverse dynamics that drive the market forward. The primary and secondary types of Glioblastoma patients cater to different treatment approaches, where surgery, radiotherapy, and medications play a pivotal role in managing the disease. Patient types such as adult, geriatric, and child patients require personalized treatment strategies to address their specific needs. Drug types, including generics and branded medications, offer a spectrum of options for healthcare providers and patients. The route of administration, end-user settings, and distribution channels further shape the Glioblastoma treatment market, reflecting a multidimensional industry outlook.

**Market Players**

- F. Hoffmann-La Roche AG - Amgen Inc. - Merck & Co., Inc. - Pfizer Inc. - Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare) - ZEISS International - Amneal Pharmaceuticals LLC - Elekta - Sun Pharmaceutical Industries Ltd - Teva Pharmaceutical Industries Ltd. - Eckert & Ziegler - Accord Healthcare - Angiochem - ANI Pharmaceuticals, Inc. - Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.) - AstraZeneca - Cantex Pharmaceuticals, Inc. - CELON LABS - Diffusion Pharmaceuticals Inc. - EnGeneIC - ERC.SA. - Genenta science - Jazz Pharmaceuticals, Inc. - Loxo Oncology (A Subsidiary of Eli Lilly) - Novartis AG - VBL THERAPEUTICS - Viatris Inc. - Zydus Pharmaceuticals, Inc.

The Glioblastoma Multiforme Treatment Market is highly competitive, with a plethora of market players driving innovation and advancements in treatment options. Companies like F. Hoffmann-La Roche AG, Merck & Co., Inc., Pfizer Inc., and Novartis AG are major players in the market, offering a diverse portfolio of oncology therapies. The presence of prominent players like Amgen Inc., Teva Pharmaceutical Industries Ltd., and AstraZeneca further intensifies competition in the industry. Varian Medical Systems, Inc. and ZEISS International contribute significantly to the radiotherapy segment, providing advanced solutions for Glioblastoma patients. Biopharmaceutical companies such as Jazz Pharmaceuticals, Inc. and Loxo Oncology focus on targeted therapies, while generic manufacturers like Sun Pharmaceutical Industries Ltd and Accord Healthcare offer cost-effective medication options. The collaboration between these market players fosters innovation, research, and development initiatives, ultimately benefiting Glioblastoma patients worldwide.

DBMR Cloud-connected intelligence: Bridging the gap with revenue-impacting solutions

DBMR Cloud is a connected intelligence platform that uses a neural network to analyze and integrate macro and micro-level data, bridging the gap between data analytics, market research, and strategy for profound growth and revenue impact.

Get More Detail: https://www.databridgemarketresearch.com/nucleus/global-glioblastoma-multiforme-treatment-market

The market is highly fragmented, with a mix of global and regional players competing for market share. To Learn More About the Global Trends Impacting the Future of Top 10 Companies in Glioblastoma Multiforme Treatment Market :   https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market/companies

Key Questions Answered by the Global Glioblastoma Multiforme Treatment Market Report:

What is the current state of the Glioblastoma Multiforme Treatment Market, and how has it evolved?

What are the key drivers behind the growth of the Glioblastoma Multiforme Treatment Market?

What challenges and barriers do businesses in the Glioblastoma Multiforme Treatment Market face?

How are technological innovations impacting the Glioblastoma Multiforme Treatment Market?

What emerging trends and opportunities should businesses be aware of in the Glioblastoma Multiforme Treatment Market?

Browse More Reports:

https://www.databridgemarketresearch.com/reports/asia-pacific-glioblastoma-multiforme-treatment-markethttps://www.databridgemarketresearch.com/reports/europe-glioblastoma-multiforme-treatment-markethttps://www.databridgemarketresearch.com/reports/middle-east-and-africa-glioblastoma-multiforme-treatment-markethttps://www.databridgemarketresearch.com/reports/north-america-glioblastoma-multiforme-treatment-market

https://www.databridgemarketresearch.com/nucleus/asia-pacific-glioblastoma-multiforme-treatment-markethttps://www.databridgemarketresearch.com/nucleus/europe-glioblastoma-multiforme-treatment-markethttps://www.databridgemarketresearch.com/nucleus/north-america-glioblastoma-multiforme-treatment-market

Data Bridge Market Research:

☎ Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 982

✉ Email: corporatesales@databridgemarketresearch.com"

[industrynewsupdates]

Exploring Glioblastoma Multiforme Treatment Market : Trends and Future Outlook

The global glioblastoma multiforme treatment market size is expected to reach USD 5.10 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.7% from 2023 to 2030. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company’s Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Gather more insights about the market drivers, restrains and growth of the Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market Report Highlights

• Based on treatment, in 2020, radiation therapy dominated the market with a revenue share of 37.0% in 2022, owing to improved survival rates, as radiation therapy is most often recommended as the first line of treatment or in combination with chemotherapy and surgery

• By drug class, the others segment accounted for the largest revenue share in 2022. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)

• The hospital segment held the largest revenue share in the glioblastoma multiforme treatment market in 2022 and is anticipated to maintain its leading position during the forecast period. Patients prefer hospitals in terms of treatment accessibility and convenience

• Asia Pacific is expected to register the fastest growth rate of 11.1% over the forecast period, owing to various factors such as the entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector

• North America accounted for the largest share of 43.4% in 2022. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility to quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth

Glioblastoma Multiforme Treatment Market Segmentation

Grand View Research has segmented the global glioblastoma multiforme treatment market on the basis of treatment, drug class, end-use, and region:

Glioblastoma Multiforme Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Surgery

• Radiation Therapy

• Chemotherapy

• Targeted Therapy

• Tumor Treating Field (TTF) Therapy

• Immunotherapy

Glioblastoma Multiforme Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Temozolomide

• Bevacizumab

• Lomustine

• Carmustine Wafers

• Others

Glioblastoma Multiforme Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Clinics

• Ambulatory Surgical Centers

Glioblastoma Multiforme Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Glioblastoma Multiforme Treatment Market Intelligence Study, published by Grand View Research.

[ralfmaximus]

The discovery represents a potential new way to recruit the immune system to fight treatment-resistant cancers using an iteration of mRNA technology and lipid nanoparticles, similar to COVID-19 vaccines, but with two key differences: use of a patient’s own tumor cells to create a personalized vaccine, and a newly engineered complex delivery mechanism within the vaccine.

Within 48 hours, the four human study participants showed remarkable results: their immune systems went into turbo cancer-destroying mode. And without surgery, radiation, or dangerous chemotherapy.

Folks, we may have a cure for cancer within your lifetime.

[delveinsight12]

Understanding the Dynamics of the Glioblastoma Market: Drivers, Barriers, and Future Outlook

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive and malignant type of primary brain tumor in adults. It belongs to a group of tumors called gliomas, which arise from glial cells in the brain.

Glioblastoma Market Drivers

The glioblastoma market, which encompasses diagnostics, treatments, and supportive care for patients with glioblastoma, is influenced by several key drivers. These drivers shape the development of new therapies, diagnostic tools, and supportive care approaches aimed at improving patient outcomes. Some of the significant drivers in the glioblastoma market include:

High Unmet Medical Need: Glioblastoma represents a significant unmet medical need due to its aggressive nature, limited treatment options, and poor prognosis. The urgent need for effective therapies drives research and development efforts to discover novel treatment modalities and improve existing treatment strategies.

Advances in Molecular Biology: Increasing understanding of the molecular pathways and genetic alterations involved in glioblastoma pathogenesis has led to the identification of potential therapeutic targets. Advances in molecular biology, genomics, and tumor profiling techniques enable the development of targeted therapies tailored to the specific molecular characteristics of individual tumors.

Innovations in Immunotherapy: Immunotherapy has emerged as a promising approach for the treatment of glioblastoma. Research into immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell therapy aims to harness the immune system's ability to recognize and eliminate tumor cells. Immunotherapy holds potential for improving treatment outcomes and extending survival in glioblastoma patients.

Technological Advancements in Imaging: Technological advancements in neuroimaging, such as advanced magnetic resonance imaging (MRI) techniques, positron emission tomography (PET), and molecular imaging, enable more accurate diagnosis, tumor characterization, and treatment monitoring in glioblastoma patients. Improved imaging modalities facilitate early detection of tumor recurrence, guiding treatment decisions and improving patient management.

Precision Medicine Approaches: The shift towards precision medicine in glioblastoma treatment involves tailoring therapies to the individual molecular profile of each patient's tumor. Biomarker-driven treatment strategies, including molecular profiling, genetic testing, and tumor sequencing, help identify predictive biomarkers and select the most effective treatment options for glioblastoma patients.

Clinical Trial Innovation: Clinical trials play a critical role in evaluating the safety and efficacy of investigational therapies in glioblastoma patients. Innovative trial designs, including adaptive trials, basket trials, and umbrella trials, allow for more efficient evaluation of multiple treatment strategies and combinations. Collaborative efforts between academia, industry, and regulatory agencies drive the development of novel therapies through clinical research.

Regulatory Incentives: Regulatory agencies provide incentives and expedited pathways for the development and approval of therapies targeting rare and life-threatening diseases like glioblastoma. Orphan drug designation, fast-track designation, breakthrough therapy designation, and accelerated approval pathways facilitate the development and regulatory review of promising therapies, expediting their availability to patients.

Increasing Healthcare Investment: Rising healthcare expenditure and investment in neuro-oncology research contribute to the advancement of glioblastoma treatment options. Pharmaceutical companies, biotechnology firms, academic institutions, and government agencies allocate resources towards glioblastoma research, drug development, and clinical trials, driving innovation and progress in the field.

Glioblastoma Market Barriers

Despite ongoing efforts to develop effective treatments for glioblastoma, several barriers hinder progress in the glioblastoma market. These barriers pose challenges to research, drug development, patient care, and overall improvements in treatment outcomes. Some of the significant barriers in the glioblastoma market include:

Limited Treatment Options: Glioblastoma is notoriously difficult to treat, with few effective therapeutic options available. The aggressive nature of the disease, combined with its resistance to conventional treatments, poses significant challenges for clinicians and researchers. The lack of diverse treatment modalities contributes to the limited survival benefit and poor prognosis associated with glioblastoma.

Tumor Heterogeneity: Glioblastoma tumors are characterized by extensive molecular and cellular heterogeneity, which complicates treatment decision-making and response assessment. Intra-tumoral heterogeneity, inter-tumoral heterogeneity, and tumor evolution over time contribute to treatment resistance, disease recurrence, and therapeutic failure. Developing therapies that target the diverse subpopulations of tumor cells within glioblastoma tumors remains a significant challenge.

Blood-Brain Barrier (BBB): The blood-brain barrier presents a formidable obstacle to drug delivery in glioblastoma treatment. The BBB restricts the passage of many therapeutic agents, including chemotherapy drugs and targeted therapies, into the brain parenchyma, limiting their effectiveness. Strategies to bypass or overcome the BBB, such as nanoparticle-based drug delivery systems and focused ultrasound techniques, face technical and safety challenges in clinical translation.

Tumor Recurrence and Resistance: Glioblastoma tumors frequently recur after initial treatment, often with increased aggressiveness and resistance to therapy. Tumor recurrence is associated with the persistence of cancer stem cells, tumor microenvironmental changes, and molecular alterations that promote treatment resistance. Overcoming mechanisms of tumor recurrence and developing therapies that target resistant tumor cells are critical unmet needs in glioblastoma treatment.

Lack of Biomarkers: The absence of reliable biomarkers for glioblastoma diagnosis, prognosis, and treatment response prediction hampers personalized treatment approaches. Biomarker discovery efforts face challenges such as tumor heterogeneity, dynamic changes in biomarker expression over time, and limited validation in clinical settings. Biomarker-driven treatment strategies require robust biomarkers that accurately predict treatment outcomes and guide therapeutic decisions.

Clinical Trial Design Challenges: Clinical trials in glioblastoma face challenges related to patient recruitment, trial design, and endpoint selection. Glioblastoma patients often have complex medical histories, comorbidities, and limited eligibility criteria for clinical trials, leading to slow accrual and challenges in achieving statistical power. Additionally, determining clinically meaningful endpoints, such as overall survival and progression-free survival, in the context of glioblastoma treatment poses methodological challenges.

Regulatory Hurdles: Regulatory approval processes for new glioblastoma therapies are stringent and time-consuming, requiring substantial preclinical and clinical evidence of safety and efficacy. Challenges in demonstrating meaningful clinical benefit, establishing appropriate surrogate endpoints, and navigating regulatory pathways delay the development and approval of novel treatments. Regulatory agencies seek to balance patient safety with the need for expedited access to innovative therapies for life-threatening diseases like glioblastoma.

Limited Funding and Investment: Glioblastoma research and drug development rely heavily on funding from government agencies, philanthropic organizations, and private investors. Limited funding availability, competing research priorities, and perceived risks associated with glioblastoma drug development may deter investment in the field. Glioblastoma research often requires long-term commitments and substantial resources to overcome the scientific, clinical, and regulatory challenges inherent to the disease.

Future Glioblastoma Market Analysis

Analyzing the future of the glioblastoma market involves considering emerging trends, technological advancements, research breakthroughs, regulatory developments, and evolving patient needs. Here's a prospective analysis of the future glioblastoma market:

Advancements in Precision Medicine: The future of glioblastoma treatment lies in precision medicine approaches that tailor therapies to the molecular profile of individual tumors. Advances in molecular profiling, genomics, and biomarker discovery will enable the identification of specific therapeutic targets and predictive markers for patient stratification. Precision medicine strategies will improve treatment outcomes and reduce toxicity by matching patients with the most effective and well-tolerated therapies.

Immunotherapy Revolution: Immunotherapy holds tremendous promise for transforming the treatment landscape of glioblastoma. Ongoing research into immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell therapy aims to harness the immune system's ability to recognize and eliminate tumor cells. Combination immunotherapy approaches and innovative treatment modalities, such as oncolytic viruses and immune cell engineering, will enhance anti-tumor immune responses and overcome immune evasion mechanisms.

Targeted Therapies and Novel Drug Development: The future glioblastoma market will witness the development of targeted therapies that selectively inhibit critical signaling pathways and genetic alterations driving tumor growth and progression. Small molecule inhibitors, antibody-drug conjugates, bi-specific antibodies, and gene therapy approaches will target specific oncogenic drivers and vulnerabilities in glioblastoma tumors. Combination therapies that exploit synergistic interactions between targeted agents, immunotherapies, and standard treatments will improve therapeutic efficacy and overcome treatment resistance.

Innovative Drug Delivery Systems: Overcoming the blood-brain barrier (BBB) remains a major challenge in glioblastoma treatment. Future advancements in drug delivery systems, such as nanoparticle-based carriers, liposomes, and focused ultrasound techniques, will enhance drug penetration into the brain parenchyma and improve therapeutic efficacy. Targeted drug delivery platforms that selectively deliver therapeutic agents to tumor cells while sparing healthy brain tissue will minimize off-target effects and maximize treatment benefit.

Biomarker-Driven Clinical Trials: Biomarker-driven clinical trials will become increasingly important for evaluating targeted therapies and immunotherapies in glioblastoma patients. Molecular profiling, genetic testing, and tumor sequencing will guide patient selection, treatment allocation, and response assessment in clinical trial settings. Adaptive trial designs, basket trials, and umbrella trials will facilitate the rapid evaluation of multiple treatment strategies and combinations, accelerating the development of novel therapies.

Digital Health Integration: Digital health technologies will play a significant role in improving glioblastoma patient care and treatment outcomes. Telemedicine platforms, mobile apps, wearable devices, and remote monitoring tools will enable remote patient management, real-time symptom tracking, and virtual consultations with healthcare providers. Digital health solutions will enhance patient engagement, adherence to treatment regimens, and access to supportive care services, thereby improving quality of life and survival outcomes.

Regulatory Incentives and Expedited Pathways: Regulatory agencies will continue to provide incentives and expedited pathways for the development and approval of innovative therapies for glioblastoma. Orphan drug designation, fast-track designation, breakthrough therapy designation, and accelerated approval pathways will facilitate the regulatory review and expedited access to promising therapies for glioblastoma patients. Collaboration between regulators, industry stakeholders, and patient advocacy groups will streamline the drug development process and accelerate the availability of new treatments.

Patient-Centric Care Models: The future glioblastoma market will prioritize patient-centered care models that address the holistic needs and preferences of individuals living with glioblastoma. Multidisciplinary care teams, shared decision-making, and personalized treatment plans will optimize patient outcomes and improve quality of life. Psychosocial support, palliative care services, and survivorship programs will address the emotional, social, and supportive care needs of glioblastoma patients and their caregivers.

Evolving Glioblastoma Treatment Outlook

The evolving treatment outlook for glioblastoma involves a multifaceted approach aimed at improving patient outcomes through advances in precision medicine, immunotherapy, targeted therapies, innovative drug delivery systems, and supportive care. Here's an overview of the evolving glioblastoma treatment outlook:

Precision Medicine: The future of glioblastoma treatment lies in precision medicine approaches that tailor therapies to the individual molecular characteristics of each patient's tumor. Molecular profiling, genetic testing, and biomarker analysis guide treatment decisions, allowing for the selection of targeted therapies that address specific genetic alterations and signaling pathways driving tumor growth. Precision medicine strategies improve treatment efficacy, minimize toxicity, and overcome resistance mechanisms, ultimately leading to better outcomes for glioblastoma patients.

Immunotherapy Revolution: Immunotherapy represents a transformative approach to glioblastoma treatment by harnessing the immune system's natural ability to recognize and eliminate cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell therapy are being investigated in clinical trials for glioblastoma. These immunotherapeutic approaches enhance anti-tumor immune responses, overcome immunosuppressive mechanisms within the tumor microenvironment, and improve long-term survival outcomes in a subset of patients.

Targeted Therapies: Advances in molecular biology and drug development have led to the identification of specific molecular targets and signaling pathways implicated in glioblastoma pathogenesis. Targeted therapies, such as small molecule inhibitors, antibody-drug conjugates, and bi-specific antibodies, selectively inhibit oncogenic drivers and vulnerabilities in glioblastoma tumors. Combination therapies that target multiple signaling pathways or exploit synergistic interactions between targeted agents and immunotherapies show promise in overcoming treatment resistance and improving therapeutic outcomes.

Innovative Drug Delivery Systems: Overcoming the blood-brain barrier (BBB) remains a significant challenge in glioblastoma treatment. Innovative drug delivery systems, including nanoparticle-based carriers, liposomes, and focused ultrasound techniques, enhance drug penetration into the brain parenchyma and improve therapeutic efficacy. Targeted drug delivery platforms enable the selective delivery of therapeutic agents to tumor cells while sparing healthy brain tissue, minimizing off-target effects and maximizing treatment benefit.

Combination Therapies: Combination therapy approaches that combine standard treatments (surgery, radiation therapy, chemotherapy) with targeted therapies, immunotherapies, and innovative drug delivery systems are being explored to improve treatment outcomes in glioblastoma. Rational combinations that target complementary pathways or overcome treatment resistance mechanisms offer synergistic effects and enhanced therapeutic efficacy. Clinical trials evaluating combination regimens are ongoing to identify optimal treatment strategies for glioblastoma patients.

Supportive Care and Symptom Management: In addition to anti-tumor therapies, supportive care and symptom management play a crucial role in optimizing quality of life for glioblastoma patients. Palliative care services, psychosocial support, pain management, and symptom relief interventions address the physical, emotional, and social needs of patients and their caregivers throughout the disease trajectory. Integrating supportive care into comprehensive treatment plans improves patient well-being, enhances treatment tolerance, and ensures holistic care delivery.

Clinical Trial Innovation: Clinical trials remain essential for evaluating novel treatments and advancing the standard of care for glioblastoma. Innovative trial designs, biomarker-driven approaches, and adaptive strategies facilitate the rapid evaluation of promising therapies in glioblastoma patients. Collaboration between academia, industry, regulatory agencies, and patient advocacy groups accelerates the translation of scientific discoveries into clinical practice and drives progress in glioblastoma treatment.

Patient-Centered Care Models: Patient-centered care models prioritize the individual needs, preferences, and values of glioblastoma patients throughout their treatment journey. Multidisciplinary care teams, shared decision-making, and personalized treatment plans empower patients to actively participate in their care and make informed treatment choices. Patient support programs, educational resources, and survivorship initiatives promote patient engagement, resilience, and empowerment in coping with the challenges of glioblastoma.

Role of Companies in the Glioblastoma Market

In the Glioblastoma market, companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others play a pivotal role in driving innovation, research, development, and the provision of treatments and therapies for individuals suffering from this chronic inflammatory skin condition. These companies encompass pharmaceutical giants, biotechnology firms, medical device manufacturers, and healthcare service providers, each contributing uniquely to the advancement of Glioblastoma management. Pharmaceutical companies lead the charge in developing novel drugs, ranging from topical corticosteroids to biologics targeting specific immune pathways implicated in Glioblastoma pathogenesis. 

Glioblastoma Market Outlook - Key Conclusion and Analysis

The Glioblastoma market is undergoing a transformative period, driven by advances in research, innovation in therapeutic approaches, and shifting treatment paradigms. While significant progress has been made in improving outcomes for patients with Glioblastoma, several barriers continue to challenge the market's expansion, including high treatment costs, safety concerns, and regulatory hurdles. Looking ahead, personalized medicine, novel therapeutic targets, and digital health solutions are poised to shape the future of Glioblastoma management, offering new hope for patients and caregivers alike. Efforts to address these challenges and capitalize on emerging opportunities will be critical in advancing the field and ultimately improving the lives of individuals living with Glioblastoma.

Get a more detailed overview, at: Glioblastoma Market Outlook and Forecast

[reasonsforhope]

"In a first-ever human clinical trial, an mRNA cancer vaccine developed at the University of Florida successfully reprogrammed patients’ immune systems to fiercely attack glioblastoma, the most aggressive and lethal brain tumor.

The results in four adult patients mirrored those in 10 pet dog patients suffering from brain tumors whose owners approved of their participation.

The discovery represents a potential new way to recruit the immune system to fight treatment-resistant cancers using an iteration of mRNA technology and lipid nanoparticles, similar to COVID-19 vaccines, but with two key differences: use of a patient’s own tumor cells to create a personalized vaccine, and a newly engineered complex delivery mechanism within the vaccine.

“Instead of us injecting single particles, we’re injecting clusters of particles that are wrapping around each other like onions,” said senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist who pioneered the new vaccine, which like other immunotherapies attempts to “educate” the immune system that a tumor is foreign.

“These clusters alert the immune system in a much more profound way than single particles would.”

Among the most impressive findings was how quickly the new method spurred a vigorous immune-system response to reject the tumor, said Sayour, principal investigator at the University’s RNA Engineering Laboratory and McKnight Brain Institute investigator who led the multi-institution research team.

“In less than 48 hours, we could see these tumors shifting from what we refer to as ‘cold’—very few immune cells, very silenced immune response—to ‘hot,’ very active immune response,” he said.

“That was very surprising given how quick this happened, and what that told us is we were able to activate the early part of the immune system very rapidly against these cancers, and that’s critical to unlock the later effects of the immune response,” he explained in a video (below).

Glioblastoma is among the most devastating diagnoses, with median survival around 15 months. Current standard of care involves surgery, radiation and some combination of chemotherapy.

The new report, published May 1 in the journal Cell, is the culmination of seven years of promising studies, starting in preclinical mouse models.

In the cohort of four patients, genetic material called RNA was extracted from each patient’s own surgically removed tumor, and then messenger RNA (mRNA)—the blueprint of what is inside every cell, including tumor cells—was amplified and wrapped in the newly designed high-tech packaging of biocompatible lipid nanoparticles, to make tumor cells “look” like a dangerous virus when reinjected into the bloodstream to prompt an immune-system response.

The vaccine was personalized to each patient with a goal of getting the most out of their unique immune system...

While too early in the trial to assess the clinical effects of the vaccine, the patients either lived disease-free longer than expected or survived longer than expected. The 10 pet dogs lived a median of 4.5 months, compared with a median survival of 30-60 days typical for dogs with the condition.

The next step, with support from the Food and Drug Administration and the CureSearch for Children’s Cancer foundation, will be an expanded Phase I clinical trial to include up to 24 adult and pediatric patients to validate the findings. Once an optimal and safe dose is confirmed, an estimated 25 children would participate in Phase 2."

-via Good News Network, May 11, 2024

-video via University of Florida Health, May 1, 2024

[kooffeecup]

Fading Forever

" Stay with me forever,'' he’d once begged. Now, forever was a hollow, endless thing.   

genre : angst, romance. ( mention of terminal illness )

— fading forever

The first time Jungkook saw you, you were laughing. It was a sound that cut through the monotony of his 9-to-5 life a life of spreadsheets, lukewarm coffee, and subway rides under flickering fluorescent lights. You were holding a dripping ice cream cone, arguing playfully with the vendor over a mistaken order. He’d offered you his napkin, fingers brushing yours, and when you grinned up at him, he swore the sun had burst through Seoul’s perpetual gray.  

For two years, you painted his world in hues he didn’t know existed. Mornings tangled in sheets, your breath warm against his neck. Evenings spent on your cramped apartment floor, sharing takeout as you rewrote the lyrics to cheesy love songs, replacing every “baby” with “Jungkook-ah” just to make him blush. He’d trace the constellation of freckles on your shoulder and whisper, “Stay with me forever,” and you’d laugh, saying forever was too short for the two of you. But forever had a different plan.  

The headaches started in spring. You blamed stress, dehydration, the stale air of your office. But when you collapsed in the grocery store, your hand slipping from Jungkook’s as you reached for a box of strawberry milk, the MRI lit up like a grenade had gone off in your brain. Glioblastoma multiforme. Stage IV. The doctor’s voice was a distant hum as Jungkook’s knees hit the linoleum floor.  

You held his face that night, thumbs wiping tears he didn’t realize he’d shed. “It’s okay,” you lied. “We’ll fight it.”  

Chemo stole your laughter first. Then your hair, your appetite, the light in your eyes. Jungkook quit his job, selling his guitar and the vintage Levi’s jacket he’d loved to pay for treatments that did nothing but make you vomit. He learned to inject morphine into your IV, his hands steady even as his soul fractured.  

 

One sleepless 3 a.m., you rasped, “I’m sorry,” and he shattered. “Don’t you *dare* apologize,” he choked, forehead pressed to your bony knuckles. “You’re my everything. You’re—”  

“Your forever,” you finished, smiling weakly. “But Jungkook-ah… forever’s running out.”  

The hospice bed swallowed you whole. Machines beeped a cruel countdown as Jungkook clung to your hand, memorizing the feel of your pulse—thready, irregular, *fading*. You struggled to speak, and he leaned close, your breath a ghost against his ear.  

“Don’t… let go,” you pleaded.  “Never,” he wept. “I’ll never let go.”  

But you were already slipping. Your last words were a sigh, a half-formed “I love—” before the monitors flatlined.  

He visits your grave every Sunday. Today, he brings a strawberry milk carton and a napkin, the ink blurred from rain or tears. The engraving reads, “YN – Forever Wasn’t Long Enough.” 

As he turns to leave, a laugh rings out—a girl at a nearby vendor’s stall, arguing over a mistaken order. For a heartbeat, he sees you. But the moment passes, and he walks home alone, the echo of your voice haunting every step.  

“Stay with me forever,” he’d once begged.  Now, forever was a hollow, endless thing.  

[scobbe]

Yesterday one of our most beloved parishioners (and the organist’s best friend) passed away, after three years undergoing treatment for glioblastoma (which some of us here, I know, are aware of how it steals people away before their time). We all knew the day was coming but it was so sudden at the end, a trip to the ER then the next day he was gone. Prayers and kind thoughts please for his wonderful and amazing wife who has been through the worst of it, as well as our organist who is going to be lost without him.

And if you hear a soft kind voice singing today, know you are blessed.

[angryschnauzer]

Update 3th April 2024

How are we into the 4th month of the year already? This year is slipping away so quickly. Anyway, my husband finished Radiotherapy mid Feb, had a few weeks off treatment, and is now on 6 cycles of strong chemotherapy. He has 5 days on tablet dose, then 23 days off, so its a 4 week cycle. We had an update meeting with his Neurologist. The tumour hasn't started to grow back, but we've got to add a 'yet' to that. The type of brain tumour (Glioblastoma) is an incredibly agressive form of brain cancer, spreading tendrils out into the crevices of the brain that there is never any way of scooping the whole thing out and getting every last bit with surgery. Thus the Radiotherapy and chemotherapy to try and blast - i cant think of a better word - as much remaining cancer as it can. He'll have regular MRI's to monitor any regrowth etc, and as he's mid 40's if he's strong enough he can have surgery again.

So now we're at the start of April and to be honest the last three months have been horrible. At the start of the year i caught a cough that developed into Bronchitis, and then by mid March i was so ill it was Pneumonia. When Hubby was on his 'rest' weeks post radiotherapy he was unable to rest as he had to help me care for our son. Sidenote; our Son's type 1 diabetes has been somewhat out of control during this time too. Two weeks ago i was admitted to the emergency dept at Hospital with chest pains. Hardly surprising with the amount of stress i'm under, but it turned out to be caused by bruising my internal chest muscles from coughing so much due to the pneumonia. Doctors told me i must rest. Well, the universe decided it didn't like that option and the day after Hubby went down with a cold/flu like virus, and because of his cancer treatment all but destroying his immune system, it's knocked him sideways. We're now 10 days later and its still in full force. I had to take him to the cancer hospital yesterday to have blood tests to ensure it hadn't turned bacterial (it hasn't) but we've been having awful nights sleep for the both of us which means neither of us are recovering at a rate we need.

So that's were we're at. Its just a massive cycle of illness followed by illness and it feels like we can't get out of it.

[fireflowersims]

Death, dying and funerals in the Netherlands (pt 1)

Not even sure which tw's I should tag this with. Keep scrolling if you think it might be distressing.

So, your loved one has died and now you have to deal with the body. If you've watched YouTube videos about this subject before (like Caitlin Doughty/Ask a Mortician), you may have a certain (very US-centric) view on what comes next. Probably quite relevant to many y'all tumblrinas and all, but I'm not from there, our traditions in the Netherlands are very different. My dad passed away this monday and since we're in the midst of the process I may as well get detailed about how we do it here. I personally think it is a good way to go about it.

I'll make a few posts because it's a lot to cover and I'm trying to be detailed. This is part 1. I'll put a link to part 2 under the spoiler as soon as I've written it. There are no pictures. Only text.

So, tw on all of this: cancer, death, dying, corpses, handling corpses in various ways, funerals, undertakers, huge sums of money, insurance company (derogatory), religion

So there's a corpse in your house

Your loved one has just died at home. Perhaps of illness, perhaps an accident, who knows.

I will not go into detail about my dad's actual passing and the whole process of dying. It's anything but pleasant. In the end, he died of brain cancer. He passed at home, pain free, in his own bed. He will be buried.

The first thing you do is to call the doctor. You call your (or your loved one's) GP during their office hours. At night and during the weekend you call the HAP (Huisartsenpost aka the hospital GP).

If your loved one died as a result of a terminal illness (like brain cancer (glioblastoma) in my dad's case), they were probably under the care of at-home (palliative) nursing. You call them as well. Chances are they'll need to unhook some medical equipment.

After a bit, the doctor serving as coroner (schouwarts) will show up to your house to confirm the death. They will listen for a heartbeat and check the eyes for responsiveness. After they are sure the person is indeed dead, they will fill in some forms needed for the municipality. These forms will get picked up by the funeral home or you can bring them to the municipality yourself. You need those forms to get a death certificate.

After the doctor has filled in these forms, you can call your funeral insurance (often DELA or Monuta nowadays) and/or a funeral home of your choosing. The insurance stuff can get a bit complex and oh my will I elaborate on this later, but basically, as soon as you tell the funeral home/insurance that you want to make use of their services, they will ask for some details including size of the diseased and if you would like them to be viewed and if so: where? Also, how should the body be displayed? On the bed, on a gurney covered in a shroud, in a coffin (not a casket!) or even on a fake bed? You have options. We went for a coffin. The simplest model. Made out of untreated wood, cotton lining, no metal bits, fit for natural burial.

Once they know the details, they will then send people to your house to take care of the body. It can take a couple hours for them to arrive depending on the time and how busy it is. This leaves some time to pick the outfit they will be buried in.

The final care

When the funeral workers arrive, you get an often very emotional and tender part of the process.

In the Netherlands, embalming is illegal. It used to be possible to get a treatment called "thanatopraxie" which is a light temporary embalming that lasts no longer than 10 days, but last I checked this is currently not possible as it involves carcinogens or smth like that.

This means that almost all viewings that take place in the Netherlands are of unembalmed bodies. Simply said: my dad looks dead. He does not look like he's sleeping. He is very visibly dead. There is no mistaking it for sleep. The body is discolored to some degree, it is very much a corpse.

The body still gets "prepped" though. Mostly non-invasive.

In my dad's case he was upstairs and so he needed to be brough down the stairs for the final care. This involves a "bodypod": a type of mattress that they strapped him to for transport. We had to rearrange almost all the living room furniture to make room for this, the coffin and to be able to give him his final care. He's a big guy.

NOTE: We chose to initially keep him at home, then have him transferred elsewhere the next day. Chances are this process may be done elsewhere if you immediately want to get the body out of the house. I'm not 100% sure on this.

Next, the body gets laid on a gurney, a sheet below.

This is where the family involvement can really start. Almost all processes below can be performed either by the caretakers from the funeral home or by the family. In my dad's case, it was primarily my mom and I helping. With a minor role for my cousin.

The body gets undressed completely and cleaned. It is possible for family members to assist with this. I did.

First the genitalia gets cleaned, I opted not to do this. Then the body gets a diaper so that any leakage gets caught and won't cause any undue.... Issues. Then the rest of the body gets washed with a disposable washcloth (I did this). It is also possible to use deodorant or perfume if you wish to. My mom also shaved his face.

Then you dress the body. Underwear, top, bottom, socks. Jewelry is possible but may have to be removed before burial.

The caretakers will apply a bit of make-up on request. My dad only got a bit of BB Cream. The intention of the makeup is not to make the person look alive-ish. It is to cover any discoloration (like deep purple ears thanks to gravity pulling the blood down).

I was not present for this part. Instead my cousin chose to stay with him during this process. According to her, they had issues getting his mouth open. The fact I got to him with a rolled up towel beneath his chin within minutes of his death before rigor mortis had set in (dead bodies move weird. There's no comparing it) may have contributed to this lol

Finally, the lips and eyes are closed. This is the most invasive part of it all and cannot be done by family. The lips especially can be a gnarly process as it is done by sewing them shut with a needle. For the eyes they will use silicone lenses with soft spikes on them. These may be taken out before burial.

After it is done, it is time to transfer the body to its viewing place.

In the Netherlands it's fairly common to have what they may call "home funerals". The body will be kept at home for an extended period of time before burial. Burials or cremation have to take place pretty fast. Within a week or less in most cases. But how do you keep the body from rotting? Simple. Cooling. You get an "ice plate". Kind of like the back of a refrigerator. It gets plugged into the wall and they put the coffin on top. It works so well that you can get ice at the bottom of the coffin. You also make sure to turn the heating in the room down.

Honestly, the key takeaway here is that it's fairly common and totally okay for family members to be directly involved in the care for the body. The workers will assist when needed. As there is no embalming happening, there is no reason to keep them from the body (unless it's a serious health hazard). The body will not be caked in makeup until it looks almost alive. Rather, it will be made neat, clean and presentable.

Once everything is said and done, the body is ready for viewing. You may wonder: is it distressing to see an unembalmed body? No. It is not. I saw how my dad changed from living to dying, to dead. How his body has changed little bits over the last couple days. His body will visibly keep changing until we will close his coffin and it is not distressing to me, my mom or my sisters. Truth be told, I did startle a couple times when he was in the living room. Like "oh wait there's a corpse. Damn dad, you startled me there!". It's just a bit unexpected to have a coffin there, ya know?

Truth be told, when I read a lot of American (funeral people's) opinions on viewing on unembalmed bodies, it seems... Odd. I think it would be more disturbing to me to see an embalmed body to be honest. It is okay for a dead body to look like a dead body. In a way, it helps you come to terms with the process. To advice the family against viewing their loved one because they aren't embalmed or to praise and advertise the techniques for how it "restores the body" just doesn't feel right. It's a corpse, it doesn't need to look alive.

Moving the body

What they don't tell you about moving dead bodies is the farts, the gasses, the stench. Decomposition starts pretty much immediately and even with cooling, you're gonna get fumes eventually, especially if you move the body.

Anyways, the process of getting my dad into the coffin involved me, my mom, my cousin and the two funeral workers all working together to grab the sheet he was on and on the count of three lift him up to move him into the coffin. This went well. The funeral caretakers then helped arrange his body so it actually looked presentable.

My dad was moved uhhh, more times than desirable to be honest partially thanks to the shape of our hallway and the size of him and his coffin as well as some other stuff. And it can get stinky. Corpse gasses be stinky yo. The stench is the most tolerable near the feet, but the people at the head and chest got a face full of corpse stink upon lifting him when we had to move him out of the coffin again.

First, off the bed, down the stairs to his coffin. Then, out of the coffin to the gurney to the mortuary. Then from the mortuary to the 24h room and into his coffin again. Not sure in which order the last move happened. Later on, he will be moved again, but that is on the day of the funeral which will still take a few days.

Oh wait, I forgot to mention the whole crematory fuckery. That will be for the next post. This one is getting pretty long. Spoiler alert: 90 FUCKING EUROS?!!??

Part 2

[darkmaga-returns]

Scientists have predicted that the vaccinated population will soon see a sharp rise in turbo cancer diagnoses in the next few years.

Following the news that Fox News contributor and doctor Kelly Powers died Sunday following a heart attack and a battle with turbo cancer, scientists have warned that the majority of the public should be prepared to suffer a similar fate.

Dailymail.co.uk reports: Dr Powers — who did ballet, running and horse riding and was otherwise in good health —tragically leaves behind a young son. 

And experts are worried there will be more cases like hers in the coming decades because glioblastomas on the rise among all age groups.

Dr Powers is one of the 10,000 Americans to die from glioblastoma every year, including Senator John McCain and Beau Biden. 

But diagnoses are expected to rise by up to 75 percent by 2050.

What’s particularly concerning about these cancers is not only the speed with which they kill, there are also a lack of treatments able to successfully combat it.

Dr Powers had started suffering from frequent headaches in 2020 when she eventually had a grand mal seizure, the most serious type. 

In an interview with Preferred Health Magazine, she said her father found her passed out on the floor foaming at the mouth. 

She was rushed for a CT scan, which revealed the tumor and required emergency surgery. 

Dr Powers underwent three brain surgeries, as well as chemotherapy, radiation, and immunotherapy.

During the first operation, doctors even told her that her surrogate was pregnant with her son, who is now three years old. 

[whovian-on-ice]

i'm really sorry for this please don't read if you don't want to hear my complaining about how shit my life is.

once again i'm having the worst time. i think the saying is that things get worse before they get better or something like that.

it's been years and i could not say one good thing that happend only awful horrible thing.. i'm not exaggerating this time.

the last 4 years of my life have been real shit.

first my grandma got sick and died shortly after. then my cat i know it's not a human but i really loved him and he was so young i was so devastated. after that it was my mom who got sick.. she is still alive but not well... she is still struggling every day. she has one of the worst things that could happen to someone. she has glioblastoma, she had an operation but they could not take everything.. and of course because why not it came back again.. she is getting treatment and for now she is not getting worse. i hope she won't. i'm greatful that she is still with me. we have good days and bad days, when she can't understand what i'm saying like at all. i'm just so angry because this is so unfair ...she is the best person i know. she is sooo good to everyone.. why...

i've been unemployed for 11 months now. which is fine i'm home looking after mom.. helping her. it sounds really bad but i don't even know how i would go back to work i really don't want to... i have so many (self-diagnosed mental illnesses, depression for sure, anxiety but more then one kind, social and health anxiety for sure) i feel like i don't belong with people. and i'm not really good at anything ... i'm really just a useless waste of space.. the only thing keeping me from ending it is that i'm so fucking scared of death... which seems a bit contradicory ... whatever

the last thing.. the reason i started to vent... it seems like my other cat will also die. this cat came not long after the other cat died..(he was called Maci, and this "new" cat is called Picúr) like a miracle came to save me. now about 3 years later we took him to a vet because he seemed hurt he couldn't jump.. it turns out he probably has FIP. we still need tests but the vet did an ultrasound and he said it is probably FIP...

i feel so hopeless when will this torture end.

if you read all of this i'm sorry.

[frothlad]

Apparently, being exposed to rabies risk is now a Republican cause? Something about a pet squirrel euthanized to check for rabies?

Your reminder that rabies will KILL YOU DEAD. There is no surviving rabies once symptoms appear. You WILL DIE.

This is one of the few absolutes in life. Look, I grew up under the threat of nuclear annihilation: Rabies is scarier.

Your manly male immune system won't save you. Your faith in Brother Robert Kennedy won't save you.

If you are exposed to rabies, and symptoms appear, sign your will immediately before you lose the ability to, because this is worse than tetanus, it's worse than glioblastoma, it's worse than anything else in the medical lexicon. You die, you die ugly, you die inhuman, you die slow enough that everyone who loves you is traumatized.

If you are exposed to rabies, you get the treatment immediately, and you say thank you to everyone in the public health system for trying to keep everyone else safe, and that includes saying goodbye to your unvaccinated pets.

This is not political. This is the reality.

Rabies does not fuck around. Do not fuck around with rabies.